Get the Stockscreener App
21.90
0.41%
-0.09
After Hours:
21.27
-0.63
-2.88%
Elanco Animal Health Inc stock is traded at $21.90, with a volume of 3.65M.
It is down -0.41% in the last 24 hours and up +1.39% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$21.99
Open:
$21.93
24h Volume:
3.65M
Relative Volume:
0.68
Market Cap:
$10.88B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
54.75
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
-5.89%
1M Performance:
+1.39%
6M Performance:
+63.07%
1Y Performance:
+80.69%
1-Day Range:
$21.71
$22.03
1-Week Range:
$21.60
$23.39
52-Week Range:
$8.02
$23.70
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
21.90 | 10.93B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
What downside risks could hit Elanco Animal Health Incorporated stockJuly 2025 PostEarnings & Fast Entry Momentum Trade Alerts - Newser
Will Elanco Animal Health Incorporated (5EA) stock outperform benchmarksOptions Play & Long-Term Investment Growth Plans - Newser
Why retail traders accumulate Elanco Animal Health Incorporated stockQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - Newser
Why institutional investors increase stakes in Elanco Animal Health Incorporated stockWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Channing Capital Management LLC Decreases Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Aquatic Veterinary Market Set to See Booming Growth 2025-2032 - openPR.com
Is Elanco Animal Health Incorporated stock vulnerable to rate hikesTrade Analysis Summary & Capital Efficiency Focused Strategies - Newser
SG Americas Securities LLC Sells 70,517 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Will Elanco Animal Health Incorporated stock beat international competitionMarket Trend Review & Expert-Curated Trade Recommendations - Newser
Elanco Animal Health (NYSE: ELAN) reports 10,314-share equity grant to director - Stock Titan
Elanco (ELAN) director reports 10,314-share deferred stock unit award - Stock Titan
Elanco (NYSE: ELAN) director R. David Hoover reports 10,314-share board equity award - Stock Titan
Elanco (ELAN) board director receives 10,314 deferred stock units in annual grant - Stock Titan
Elanco Animal Health (ELAN) director reports 10,314-share deferred stock grant - Stock Titan
Elanco (ELAN) director awarded 10,314 deferred stock units in Form 4 filing - Stock Titan
Can Elanco Animal Health Incorporated (5EA) stock retain market dominance - Newser
Legal & General Group Plc Boosts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Position Raised by Brandes Investment Partners LP - MarketBeat
Can Elanco Animal Health Incorporated (5EA) stock deliver consistent EPS growthJuly 2025 Action & Momentum Based Trading Ideas - Newser
Will Elanco Animal Health Incorporated (5EA) stock boost dividends furtherTake Profit & Low Drawdown Investment Ideas - Newser
Is Elanco Animal Health Incorporated stock vulnerable to regulatory risksLong Setup & Weekly Watchlist of Top Performers - Newser
mRNA Vaccines for Animals Market Forecast 2025-2032: Emerging - openPR.com
Creative Planning Increases Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (NYSE:ELAN) Stock Steady on Sector Review - Kalkine Media
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ensign Peak Advisors Inc Cuts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (ELAN) Is Up 8.6% After FDA Clears First Cat Screwworm Treatment – Has the Bull Case Changed? - Yahoo Finance
Can Elanco Animal Health Incorporated stock beat market expectations this quarterJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Rockefeller Capital Management L.P. Purchases 13,893 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Aug Decliners: Is Elanco Animal Health Incorporated stock dividend yield sustainableIPO Watch & High Return Trade Guides - BỘ NỘI VỤ
Elanco Animal Health Announces $245M Stock-For-Stock Acquisition Of Aratana Therapeutics - AOL.com
Elanco executive appointed as Neurizon’s board observer By Investing.com - Investing.com Canada
Elanco executive appointed as Neurizon's Board Observer - Yahoo Finance
Prudential Financial Inc. Sells 1,773,395 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - Finviz
Top Animal Health Stocks: Elanco Leads with Innovation, Zoetis Faces Headwinds - Investing.com Canada
Analysts Set Expectations for ELAN FY2025 Earnings - MarketBeat
Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4) - Quantisnow
Elanco Animal Health (NYSE:ELAN) Rating Increased to Strong-Buy at KeyCorp - MarketBeat
Elanco (ELAN) Gains FDA Emergency Use Authorization for Credelio CAT - GuruFocus
Elanco (ELAN) Upgraded to Overweight, Targets $27 Per Share - GuruFocus
Elanco's Credelio CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats - Finviz
Elanco (ELAN) Gains FDA Emergency Use Approval for Cat Treatment - GuruFocus
Elanco stock rises after FDA emergency authorization for cat screwworm treatment - Investing.com Canada
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats - Reuters
Elanco wins Overweight rating, Zoetis Sector Weight as KeyBanc reviews animal health space - Seeking Alpha
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats - Nasdaq
Elanco Animal Health Stock Is Undervalued: AnalystElanco Animal Health (NYSE:ELAN) - Benzinga
Elanco Animal Health rises as KeyBanc joins bull camp - TradingView
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):